Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 11 Mar 2022
ATAGI update following weekly COVID-19 meeting (9 March 2022)
11 March 2022 - ATAGI have not made any new updates since 2 March 2022. ...
Posted by Michael Wonder on 11 Mar 2022
Diabetes NZ to kick-start campaign for PHARMAC funding for glucose monitors
11 March 2022 - Diabetes NZ wants PHARMAC to fund next-generation blood sugar monitors for people with the debilitating disease. ...
Posted by Michael Wonder on 11 Mar 2022
Allogene Therapeutics receives FDA fast track designation for its first solid tumour candidate, ALLO-316 in the treatment of renal cell carcinoma
10 March 2022 - ALLO-316 is an allogeneic CAR T therapy candidate targeting CD70, which has broad potential application across a ...
Posted by Michael Wonder on 11 Mar 2022
Janssen seeks approval of a new indication for Imbruvica (ibrutinib) for use in patients with untreated mantle cell lymphoma
8 March 2022 - Application based on Phase 3 SHINE study results, which investigated the safety and efficacy of all-oral ...
Posted by Michael Wonder on 10 Mar 2022
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea
9 March 2022 - NICE has published evidence based recommendations on the use of solriamfetol hydrochloride (Sunosi) for the treatment ...
Posted by Michael Wonder on 10 Mar 2022
Ronapreve: first COVID-19 therapeutic drug to get Medsafe's approval not effective against Omicron
10 March 2022 - The first new COVID-19 therapeutic drug to get Medsafe's approval demonstrates "significantly diminished potency" against Omicron. ...
Posted by Michael Wonder on 10 Mar 2022
Health Canada approves Samsung Bioepis and Biogen’s Byooviz (SB11), Lucentis biosimilar (ranibizumab)
10 March 2022 - Byooviz becomes the first Lucentis biosimilar to be approved in Canada following its approval in Europe and ...
Posted by Michael Wonder on 10 Mar 2022
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea
9 March 2022 - NICE has published evidence based recommendations on the use of pitolisant hydrochloride for the treatment of ...
Posted by Michael Wonder on 10 Mar 2022
Servier submits a marketing authorisation application to the EMA for Tibsovo (ivosidenib) for patients with IDH1 mutated acute myeloid leukaemia and cholangiocarcinoma
10 March 2022 - The submission covers countries of the European Union as well as Iceland, Liechtenstein and Norway. ...
Posted by Michael Wonder on 10 Mar 2022
AARP launches new ad showing the impact of Congress’ failure to act on prescription drug prices
10 March 2022 - AARP launched new television and digital advertising featuring Larry Zarzecki, a retired law enforcement officer with Parkinson’s ...
Posted by Michael Wonder on 10 Mar 2022
SMC accepts Lumykras (sotorasib) for locally advanced or metastatic non-small cell lung cancer for use on an interim basis by NHS Scotland
7 March 2022 - Sotorasib Is indicated as monotherapy for the treatment of adult patients with KRAS G12C mutated locally advanced ...
Posted by Michael Wonder on 10 Mar 2022
How will reimbursement for Tecentriq in liver cancer affect biosimilars?
10 March 2022 - Roche is negotiating with the government over the reimbursement price of Tecentriq (atezolizumab), which passed the ...
Posted by Michael Wonder on 10 Mar 2022
Revance resubmits biologics license application for daxibotulinumtoxinA for injection for glabellar lines to the FDA
8 March 2022 - Revance Therapeutics today announced it has resubmitted its biologics license application to the U.S. FDA for DaxibotulinumtoxinA ...
Posted by Michael Wonder on 10 Mar 2022
Thirty six medicines added to PHARMAC’s waiting list as New Zealand’s medicines crisis worsens
10 March 2022 - PHARMAC has just released its Options for Investment list, which includes 36 new medicines since it ...
Posted by Michael Wonder on 10 Mar 2022
Legislation would set expiration for FDA’s accelerated approvals
9 March 2022 - New legislation, introduced by a top Democrat in the House of Representatives, would codify the U.S. ...